James C Poling

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2458355/publications.pdf

Version: 2024-02-01

126907 133252 4,230 59 33 59 citations g-index h-index papers 60 60 60 4251 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Modafinil does not reduce cocaine use in methadone-maintained individuals., 2022, 2, 100032.		1
2	Feasibility and effects of galantamine on cognition in humans with cannabis use disorder. Pharmacology Biochemistry and Behavior, 2019, 181, 86-92.	2.9	10
3	Carvedilol does not reduce cocaine use in methadone-maintained cocaine users. Journal of Substance Abuse Treatment, 2017, 73, 63-69.	2.8	5
4	A Complex Interplay between Personality Domains, Marital Status and a Variant in CHRNA5 on the Risks of Cocaine, Nicotine Dependences and Cocaine-Induced Paranoia. PLoS ONE, 2013, 8, e49368.	2.5	7
5	Sertraline delays relapse in recently abstinent cocaineâ€dependent patients with depressive symptoms. Addiction, 2012, 107, 131-141.	3.3	36
6	Randomized, double blind, placebo-controlled trial of disulfiram for the treatment of cocaine dependence in methadone-stabilized patients. Drug and Alcohol Dependence, 2011, 113, 184-191.	3.2	61
7	5-HTTLPR as a potential moderator of the effects of adverse childhood experiences on risk of antisocial personality disorder. Psychiatric Genetics, 2011, 21, 240-248.	1.1	50
8	Galantamine improves sustained attention in chronic cocaine users Experimental and Clinical Psychopharmacology, 2011, 19, 11-19.	1.8	37
9	The safety of modafinil in combination with oral â^†9-tetrahydrocannabinol in humans. Pharmacology Biochemistry and Behavior, 2011, 98, 94-100.	2.9	17
10	Behavioral effects of γ-hydroxybutyrate in humans. Behavioural Pharmacology, 2010, 21, 332-342.	1.7	28
11	<i>ADH1A</i> variation predisposes to personality traits and substance dependence. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2010, 153B, 376-386.	1.7	12
12	Effect of PTSD Diagnosis and Contingency Management Procedures on Cocaine Use in Dually Cocaine― and Opioidâ€Dependent Individuals Maintained on LAAM: A Retrospective Analysis. American Journal on Addictions, 2010, 19, 169-177.	1.4	12
13	The Safety and Efficacy of Varenicline in Cocaine Using Smokers Maintained on Methadone: A Pilot Study. American Journal on Addictions, 2010, 19, 401-408.	1.4	51
14	Variation in the Nicotinic Acetylcholine Receptor Gene Cluster CHRNA5–CHRNA3–CHRNB4 and Its Interaction with Recent Tobacco Use Influence Cognitive Flexibility. Neuropsychopharmacology, 2010, 35, 2211-2224.	5.4	26
15	Confirmation and Generalization of an Alcohol-Dependence Locus on Chromosome 10q. Neuropsychopharmacology, 2010, 35, 1325-1332.	5.4	9
16	Variation in Nicotinic Acetylcholine Receptor Genes is Associated with Multiple Substance Dependence Phenotypes. Neuropsychopharmacology, 2010, 35, 1921-1931.	5.4	103
17	Interaction of FKBP5 with Childhood Adversity on Risk for Post-Traumatic Stress Disorder. Neuropsychopharmacology, 2010, 35, 1684-1692.	5.4	299
18	Adverse childhood events as risk factors for substance dependence: Partial mediation by mood and anxiety disorders. Addictive Behaviors, 2010, 35, 7-13.	3.0	203

#	Article	IF	CITATIONS
19	Cocaine Vaccine for the Treatment of Cocaine Dependence in Methadone-Maintained Patients. Archives of General Psychiatry, 2009, 66, 1116.	12.3	241
20	Cognitive Flexibility is Associated with KIBRA Variant and Modulated by Recent Tobacco Use. Neuropsychopharmacology, 2009, 34, 2508-2516.	5.4	28
21	Interaction between Two Independent CNR1 Variants Increases Risk for Cocaine Dependence in European Americans: A Replication Study in Family-Based Sample and Population-Based Sample. Neuropsychopharmacology, 2009, 34, 1504-1513.	5.4	56
22	Atomoxetine Attenuates Dextroamphetamine Effects in Humans. American Journal of Drug and Alcohol Abuse, 2009, 35, 412-416.	2.1	31
23	Interactive Effect of Stressful Life Events and the Serotonin Transporter 5-HTTLPR Genotype on Posttraumatic Stress Disorder Diagnosis in 2 Independent Populations. Archives of General Psychiatry, 2009, 66, 1201.	12.3	221
24	The Effect of Cannabis Compared with Alcohol on Driving. American Journal on Addictions, 2009, 18, 185-193.	1.4	272
25	d-Cycloserine attenuates reactivity to smoking cues in nicotine dependent smokers: A pilot investigation. Drug and Alcohol Dependence, 2009, 104, 220-227.	3.2	84
26	Dense Genomewide Linkage Scan for Alcohol Dependence in African Americans: Significant Linkage on Chromosome 10. Biological Psychiatry, 2009, 65, 111-115.	1.3	35
27	Substance dependence low-density whole genome association study in two distinct American populations. Human Genetics, 2008, 123, 495-506.	3.8	23
28	Disulfiram enhances subjective effects of dextroamphetamine in humans. Pharmacology Biochemistry and Behavior, 2008, 90, 394-398.	2.9	16
29	Preliminary Study of Buprenorphine and Bupropion for Opioidâ€Dependent Smokers. American Journal on Addictions, 2008, 17, 287-292.	1.4	32
30	Treatment Outcome Predictors for Cocaine Dependence. American Journal of Drug and Alcohol Abuse, 2007, 33, 191-206.	2.1	108
31	Progesterone effects on cocaine use in male cocaine users maintained on methadone: A randomized, double-blind, pilot study Experimental and Clinical Psychopharmacology, 2007, 15, 453-460.	1.8	31
32	Naltrexone and Disulfiram in Patients With Alcohol Dependence and Current Depression. Journal of Clinical Psychopharmacology, 2007, 27, 160-165.	1.4	56
33	Genomewide Linkage Scan for Nicotine Dependence: Identification of a Chromosome 5 Risk Locus. Biological Psychiatry, 2007, 61, 119-126.	1.3	72
34	Clinical Efficacy of Citalopram Alone or Augmented with Bupropion in Methadone-Stabilized Patients. American Journal on Addictions, 2007, 16, 187-194.	1.4	8
35	Cocaine Withdrawal Symptoms Predict Medication Response in Cocaine Users. American Journal of Drug and Alcohol Abuse, 2006, 32, 617-627.	2.1	24
36	Genomewide Linkage Scan for Opioid Dependence and Related Traits. American Journal of Human Genetics, 2006, 78, 759-769.	6.2	125

#	Article	IF	CITATIONS
37	Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Post-Traumatic Stress Disorder. Biological Psychiatry, 2006, 60, 777-783.	1.3	125
38	Effects of topiramate in combination with intravenous nicotine in overnight abstinent smokers. Psychopharmacology, 2006, 184, 645-651.	3.1	43
39	Six-Month Trial of Bupropion With Contingency Management for Cocaine Dependence in a Methadone-Maintained Population. Archives of General Psychiatry, 2006, 63, 219.	12.3	154
40	Risperidone for Substance Dependent Psychotic Patients. Addictive Disorders and Their Treatment, 2005, 4, 1-3.	0.5	6
41	Desipramine Treatment for Cocaine Dependence in Buprenorphine- or Methadone-treated Patients: Baseline Urine Results as Predictor of Response. American Journal on Addictions, 2005, 14, 8-17.	1.4	17
42	Tiagabine affects the subjective responses to cocaine in humans. Pharmacology Biochemistry and Behavior, 2005, 82, 569-573.	2.9	18
43	Genomewide linkage scan for cocaine dependence and related traits: Significant linkages for a cocaine-related trait and cocaine-induced paranoia. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2005, 136B, 45-52.	1.7	119
44	Efficacy of dose and contingency management procedures in LAAM-maintained cocaine-dependent patients. Drug and Alcohol Dependence, 2005, 79, 157-165.	3.2	21
45	The effect of individual cocaine withdrawal symptoms on outcomes in cocaine users. Addictive Behaviors, 2005, 30, 1125-1134.	3.0	40
46	Naltrexone and Disulfiram in Patients with Alcohol Dependence and Comorbid Psychiatric Disorders. Biological Psychiatry, 2005, 57, 1128-1137.	1.3	183
47	Vaccine Pharmacotherapy for the Treatment of Cocaine Dependence. Biological Psychiatry, 2005, 58, 158-164.	1.3	202
48	Isradipine and dextromethorphan in methadone-maintained humans under a naloxone discrimination procedure. European Journal of Pharmacology, 2004, 491, 157-168.	3.5	8
49	Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia. Psychopharmacology, 2004, 172, 291-297.	3.1	109
50	Effects of reducing contingency management values on heroin and cocaine use for buprenorphine and desipramine-treated patients. Addiction, 2003, 98, 665-671.	3.3	17
51	Desipramine and contingency management for cocaine and opiate dependence in buprenorphine maintained patients. Drug and Alcohol Dependence, 2003, 70, 315-325.	3.2	113
52	Personality, substance of choice, and polysubstance involvement among substance dependent patients. Drug and Alcohol Dependence, 2003, 71, 65-75.	3.2	149
53	Prediction of Treatment Outcome by Baseline Urine Cocaine Results and Selfâ€Reported Cocaine Use for Cocaine and Opioid Dependence. American Journal of Drug and Alcohol Abuse, 2003, 29, 713-727.	2.1	54
54	D-cycloserinenaloxone interactions in opioid-dependent humans under a novel-response naloxone discrimination procedure Experimental and Clinical Psychopharmacology, 2003, 11, 237-246.	1.8	7

#	Article	IF	CITATIONS
55	Personality and substance use disorders as predictors of criminality. Comprehensive Psychiatry, 2000, 41, 276-283.	3.1	39
56	Rates of Personality Disorders in Substance Abusers: A Comparison Between DSM-III-R and DSM-IV. Journal of Personality Disorders, 1999, 13, 375-384.	1.4	21
57	Personality Disorder and Dimension Differences Between Type A and Type B Substance Abusers. Journal of Personality Disorders, 1998, 12, 1-12.	1.4	52
58	Personality Disorders in Substance Abusers: Relation to Substance Use. Journal of Nervous and Mental Disease, 1998, 186, 87-95.	1.0	132
59	Personality, temperament, and character dimensions and the DSM-IV personality disorders in substance abusers Journal of Abnormal Psychology, 1997, 106, 545-553.	1.9	170